![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | C07D 213/72 | |
A61K 45/06 | |||
A61K 31/444 | |||
A61P 3/04 | |||
C07D 401/12 |
(11) | Patento numeris | 2625172 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 11770622.6 |
Europos patento paraiškos padavimo data | 2011-10-05 | |
(97) | Europos patento paraiškos paskelbimo data | 2013-08-14 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2016-12-07 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/US2011/054841 |
Data | 2011-10-05 |
(87) | Numeris | WO 2012/047948 |
Data | 2012-04-12 |
(30) | Numeris | Data | Šalis |
390888 P | 2010-10-07 | US |
(72) |
SUTTON, Paul, Allen, US
GIRGIS, Michael, J., US
LIANG, Jessica, US
PRASHAD, Mahavir, US
VILLHAUER, Edwin, Bernard, US
|
(73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
(54) | NEW CRYSTALLINE FORMS OF THE SODIUM SALT OF (4- {4- [5- ( 6 - TRIFLUOROMETHYL - PYRIDIN- 3 - YLAMINO ) - PYRIDIN- 2 -YL]-PHENYL} - CYCLOHEXYL) -ACETIC ACID |
NEW CRYSTALLINE FORMS OF THE SODIUM SALT OF (4- {4- [5- ( 6 - TRIFLUOROMETHYL - PYRIDIN- 3 - YLAMINO ) - PYRIDIN- 2 -YL]-PHENYL} - CYCLOHEXYL) -ACETIC ACID |